Key result
Renin-angiotensin system gene polymorphisms show no association with cognitive impairment or dementia in Parkinson's disease.
Why the study?
Altered renin-angiotensin system components may be linked to neurodegeneration in Parkinson's disease, but whether genetic variability in RAS genes correlates with cognitive decline in PD is unknown.
Do genetic polymorphisms in the renin-angiotensin system correlate with cognitive decline in Parkinson's disease?
Observational (n=256)
Yes
Do genetic polymorphisms in the renin-angiotensin system correlate with cognitive decline in Parkinson's disease?
Genetic polymorphisms in the renin-angiotensin system do not appear to be directly correlated with cognitive decline in Parkinson's disease.
Answers are grounded in this paper and cite their sources.
No association supports RAS genotyping for cognitive risk in PD; leaves open other genetic contributors for longitudinal study.
BACKGROUND: Renin-angiotensin system (RAS) influences the central nervous system not only through its peripheral impact-the brain possesses its own local RAS. Studies showed altered RAS components in Parkinson's disease (PD) and their association with oxidative stress which may be linked to neurodegeneration and dementia. Moreover, the protective functions of RAS blockade antagonists against cognitive decline and dementia have been suggested. This study aimed to examine whether genetic variability in RAS genes correlates with cognitive decline in PD. METHODS AND RESULTS: We genotyped single nucleotide polymorphisms (SNPs) in angiotensinogen (AGT: rs699, rs4762), angiotensin II receptors (AGTR1: rs5186 and AGTR2: rs5194, rs1403543) genes, as well as insertion/deletion polymorphism in the angiotensin-converting enzyme (ACE I/D) gene in 256 PD patients, divided into three groups: without cognitive decline, with mild cognitive impairment and with PD dementia. We did not find any significant differences in the frequencies of the analysed polymorphisms in any of the groups. CONCLUSIONS: Despite no direct correlation between the investigated polymorphisms in RAS genes and cognitive decline in PD, we believe the impact of those genotypes may be indirect, affecting RAS blockade treatment.
No takes yet. Share an insight, caveat, or question.
Pierzchlińska et al. (2021) conducted an observational in Parkinson's disease (n=256). Genetic polymorphisms in the renin-angiotensin system (AGT, AGTR1, AGTR2, ACE) vs. Parkinson's disease patients without cognitive decline was evaluated on Association of renin-angiotensin system genetic polymorphisms with mild cognitive impairment or dementia in Parkinson's disease. Genetic polymorphisms in the renin-angiotensin system genes (AGT, AGTR1, AGTR2, and ACE) were not significantly associated with mild cognitive impairment or dementia in Parkinson's disease.
Synapse has enriched 10 related papers. Consider them for comparative context: